Education
About Us
Working with TipRanks
Follow Us
Livzon Pharmaceutical Group Inc Class H (LVZPF)
OTHER OTC:LVZPF
RESEARCH TOOLSreports
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of $3.87B. The enterprise value is $19.65B.
Market Cap$3.87B
Enterprise Value$19.65B
Share Statistics
Livzon Pharmaceutical Group has 307.05M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding307.05M
Owened by Insiders
Owened by Instutions
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$1,307,692.682
Profits Per Employee$167,979.138
Employee Count9,067
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is ―. Livzon Pharmaceutical Group’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of $11.86B and earned $1.52B in profits. Earnings per share was $2.24.
Revenue$11.86B
Gross Profit$7.77B
Operating Income$2.74B
Pretax Income$2.72B
Net Income$1.52B
EBITDA2.97B
Earnings Per Share (EPS)2.24
Cash Flow
In the last 12 months, operating cash flow was $2.57B and capital expenditures $0.00, giving a free cash flow of $2.03B billion.
Operating Cash Flow$2.57B
Free Cash Flow$2.03B
Free Cash Flow per Share$6.61
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of $0.19, resulting in a dividend yield of 5.68%
Dividend Per Share$0.19
Dividend Yield5.68%
Payout Ratio62.87%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change4.05%
50-Day Moving Average3.37
200-Day Moving Average3.35
Relative Strength Index (RSI)63.05
Average Volume (3m)0.00
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Apr 17, 2025, TBA.
Last Earnings DateMar 26, 2025
Next Earnings DateApr 17, 2025
Ex-Dividend DateJul 8, 2024
Financial Position
Livzon Pharmaceutical Group as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid $496.24M in taxes.
Income Tax$496.24M
Effective Tax Rate―
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Livzon Pharmaceutical Group has $10.81B in cash and marketable securities with $2.47B in debt, giving a net cash position of -$8.34B billion.
Cash & Marketable Securities$10.81B
Total Debt$2.47B
Net Cash-$8.34B
Net Cash Per Share-$27.16
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is $2.95, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$2.95
Price Target Upside-11.68%
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast